Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
$6.70
-20.0%
$6.70
$1.69
$14.81
$16.36MN/A102,599 shs7,639 shs
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$10.60
+21.1%
$9.15
$0.85
$47.33
$60.37M2.51.94 million shs2.57 million shs
iBio, Inc. stock logo
IBIO
iBio
$0.88
+6.0%
$0.75
$0.56
$6.89
$17.35M0.861.49 million shs727,725 shs
BiomX Inc. stock logo
PHGE
BiomX
$0.46
-37.5%
$0.48
$0.34
$2.40
$13.73M1.39347,190 shs53,300 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
0.00%0.00%0.00%+6,960.06%+1,942.68%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
+35.03%+47.55%+17.29%+159.64%-80.64%
iBio, Inc. stock logo
IBIO
iBio
-2.57%+2.81%+40.15%-13.30%-55.47%
BiomX Inc. stock logo
PHGE
BiomX
-3.78%-11.19%+1.47%+10.50%-56.40%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
$6.70
-20.0%
$6.70
$1.69
$14.81
$16.36MN/A102,599 shs7,639 shs
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$10.60
+21.1%
$9.15
$0.85
$47.33
$60.37M2.51.94 million shs2.57 million shs
iBio, Inc. stock logo
IBIO
iBio
$0.88
+6.0%
$0.75
$0.56
$6.89
$17.35M0.861.49 million shs727,725 shs
BiomX Inc. stock logo
PHGE
BiomX
$0.46
-37.5%
$0.48
$0.34
$2.40
$13.73M1.39347,190 shs53,300 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
0.00%0.00%0.00%+6,960.06%+1,942.68%
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
+35.03%+47.55%+17.29%+159.64%-80.64%
iBio, Inc. stock logo
IBIO
iBio
-2.57%+2.81%+40.15%-13.30%-55.47%
BiomX Inc. stock logo
PHGE
BiomX
-3.78%-11.19%+1.47%+10.50%-56.40%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
0.00
N/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
2.00
Hold$2.00-81.13% Downside
iBio, Inc. stock logo
IBIO
iBio
3.00
Buy$5.00466.44% Upside
BiomX Inc. stock logo
PHGE
BiomX
3.00
Buy$21.004,445.45% Upside

Current Analyst Ratings Breakdown

Latest HEB, HYPD, IBIO, and PHGE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
iBio, Inc. stock logo
IBIO
iBio
Chardan Capital
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$5.00
(Data available from 9/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
$44.44K1,358.45N/AN/A($695.52) per share-0.02
iBio, Inc. stock logo
IBIO
iBio
$375K46.27N/AN/A$1.41 per share0.63
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/A$0.70 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/A0.00N/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
-$49.82M-$58.40N/AN/AN/A-62,238.41%-876.25%-181.67%N/A
iBio, Inc. stock logo
IBIO
iBio
-$24.91M-$1.74N/AN/AN/AN/A-73.15%-45.51%N/A
BiomX Inc. stock logo
PHGE
BiomX
-$28.32M-$1.36N/AN/AN/AN/A-127.82%-56.50%N/A

Latest HEB, HYPD, IBIO, and PHGE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/13/2025Q2 2025
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/A-$2.50N/A-$2.50N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
N/AN/AN/AN/AN/A
iBio, Inc. stock logo
IBIO
iBio
N/AN/AN/AN/AN/A
BiomX Inc. stock logo
PHGE
BiomX
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/AN/AN/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
0.20
0.91
0.91
iBio, Inc. stock logo
IBIO
iBio
0.05
1.76
1.76
BiomX Inc. stock logo
PHGE
BiomX
0.51
2.84
2.84

Institutional Ownership

CompanyInstitutional Ownership
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
25.84%
iBio, Inc. stock logo
IBIO
iBio
7.90%
BiomX Inc. stock logo
PHGE
BiomX
40.57%

Insider Ownership

CompanyInsider Ownership
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
N/A
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
10.86%
iBio, Inc. stock logo
IBIO
iBio
0.58%
BiomX Inc. stock logo
PHGE
BiomX
3.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Hemispherx BioPharma, Inc stock logo
HEB
Hemispherx BioPharma
312.44 millionN/ANot Optionable
Hyperion DeFi, Inc. stock logo
HYPD
Hyperion DeFi
405.70 million5.08 millionNo Data
iBio, Inc. stock logo
IBIO
iBio
10019.66 million9.82 millionN/A
BiomX Inc. stock logo
PHGE
BiomX
12026.56 million44.04 millionNot Optionable

Recent News About These Companies

BiomX Posts Q2 Loss With 14% Cost Drop
BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript
What to Expect from BiomX's Earnings
BiomX announces going concern qualification from independent audit

New MarketBeat Followers Over Time

Media Sentiment Over Time

Hemispherx BioPharma stock logo

Hemispherx BioPharma NYSEAMERICAN:HEB

$6.70 -1.68 (-20.05%)
As of 06/13/2025

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. The company's products include Alferon N Injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and Ampligen for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of CFS, Hepatitis B, HIV, and cancer patients with renal cell carcinoma and malignant melanoma. The company was founded in 1990 and is headquartered in Orlando, Florida.

Hyperion DeFi stock logo

Hyperion DeFi NASDAQ:HYPD

$10.60 +1.85 (+21.14%)
As of 04:00 PM Eastern

Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.

iBio stock logo

iBio NYSE:IBIO

$0.88 +0.05 (+5.99%)
Closing price 04:00 PM Eastern
Extended Trading
$0.86 -0.02 (-2.23%)
As of 07:17 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

BiomX stock logo

BiomX NYSEMKT:PHGE

$0.46 -0.28 (-37.48%)
Closing price 03:58 PM Eastern
Extended Trading
$0.46 +0.00 (+0.22%)
As of 07:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. The company's product pipeline also includes BX004, a phage therapy for cystic fibrosis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. BiomX Inc. was founded in 2015 and is headquartered in Ness Ziona, Israel.